Amarin CEO on FDA's approval of key heart drug

Amarin CEO and president John Thero joins CNBC's "Power Lunch" team to discuss the drug company's FDA approval for Vascepa, a drug designed to reduce the incidence of heart attacks and strokes in high-risk patients. Amarin boosted its 2020 financial outlook following news of the approval.
Mon, Dec 16 20192:57 PM EST